adplus-dvertising
Connect with us

Health

New weight-loss drug Wegovy not a ‘magic bullet,’ doctor warns

Published

 on

As Wegovy becomes available to Canadians starting Monday, a doctor is cautioning patients wanting to use the drug to lose weight that no medication is a “magic bullet.”

Denmark-based global health-care giant Novo Nordisk produces the weekly injection Wegovy and the popular diabetic and weight-loss drug Ozempic.

The new medication is meant particularly for people who meet certain criteria related to obesity and weight, CTV’s medical expert Dr. Marla Shapiro said.

“The popularization of Ozempic being used by Hollywood and giving it the impression that it’s a magic bullet has really been not a good thing,” Shapiro said in an interview with CTV News Channel on Friday.

“The issue here is that using the medication (Wegovy) inappropriately, you may lose the weight, but if you stop the medication, you’re likely to increase back. Remember, the medication only works with exercise and a calorie-reduced diet.”

Shapiro said Wegovy is an on-label weight-loss medication, which means it’s prescribed for a specific purpose. In this case, Wegovy is prescribed to adults who are obese, with a body mass index (BMI) greater than or equal to 30. The drug also targets those who are significantly overweight, with a BMI of 27, and have at least one weight-related medical condition such as high blood pressure, Type 2 diabetes, cholesterol problems, dyslipidemia (an imbalance of lipids such as cholesterol or triglycerides), or obstructive sleep apnea.

“We really want people to understand that obesity is a chronic medical condition and that is what we’re treating,” Shapiro said. “We’re not looking to treat someone who walks in and wants to lose five pounds, 10 pounds, who really doesn’t meet those two strict criteria.”

Since Wegovy is an on-label medication for a chronic disease, it implies it’s meant for chronic use, she added.

“It needs to be monitored by your health-care provider,” she explained. “And you really have to have the indications to go on it, having failed all the other alternatives that may have been given to you prior to thinking about going on a long-term medication.”

The medication makes people feel fuller and reduces gastric emptying, or the process of the stomach expelling its contents, Shapiro said.

Who should not use Wegovy

Individuals who should not use Wegovy, according to Shapiro, include those with serious allergic reactions to the medication, those with pancreatic or renal kidney problems, those using drugs for diabetes, those who are or are planning on becoming pregnant or breastfeeding and those with a history of thyroid cancer, particularly medullary thyroid cancer.

Like other medications, she said Wegovy has side effects like constipation and nausea, which is why the drug is suggested to be used at night.

Users may also experience inflammation of the pancreas, also known as pancreatitis, gallbladder problems, lower blood sugar, kidney issues, increased heart rates, depression, suicidal thoughts and serious allergic reactions such as hives.

“No medication is benign,” she said. “It’s naive to say that any medication is without any side effects.”

Many people are overweight not necessarily because of their lifestyle choices in failing to eat less and exercise more, it’s because they have obesity as a chronic disease, Shapiro explained. “This is an illness like other illnesses and this is a tool to treat it.”

Experts estimated Wegovy would probably cost about $400 a month, though it is unclear whether medical insurance plans will cover it.

Novo Nordisk Canada declined to share the price for Wegovy to The Canadian Press. In a statement, it said that “medication pricing in Canada is influenced by multiple factors including federal, provincial and territorial governments and insurance providers, and prices may vary person to person.”

Health Canada only approved Ozempic to treat Type 2 diabetes but it has been prescribed off-label for weight loss.

The health agency later approved Wegovy in November 2021 amid supply shortages of Ozempic. Wegovy carries a higher weekly dose of semaglutide at 2.4 milligrams, compared to one milligram in a single Ozempic dose. Semaglutide, which mimics an insulin-promoting hormone, suppresses appetite and helps people feel fuller.

Clinical trials showed that Wegovy was safe and effective for weight loss, and had a positive impact on other weight-related conditions such as cardiovascular health, Vancouver-based endocrinologist Dr. Ehud Ur told The Canadian Press. Ur is not affiliated with Novo Nordisk.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Health

Canada to donate up to 200,000 vaccine doses to combat mpox outbreaks in Africa

Published

 on

 

The Canadian government says it will donate up to 200,000 vaccine doses to fight the mpox outbreak in Congo and other African countries.

It says the donated doses of Imvamune will come from Canada’s existing supply and will not affect the country’s preparedness for mpox cases in this country.

Minister of Health Mark Holland says the donation “will help to protect those in the most affected regions of Africa and will help prevent further spread of the virus.”

Dr. Madhukar Pai, Canada research chair in epidemiology and global health, says although the donation is welcome, it is a very small portion of the estimated 10 million vaccine doses needed to control the outbreak.

Vaccine donations from wealthier countries have only recently started arriving in Africa, almost a month after the World Health Organization declared the mpox outbreak a public health emergency of international concern.

A few days after the declaration in August, Global Affairs Canada announced a contribution of $1 million for mpox surveillance, diagnostic tools, research and community awareness in Africa.

On Thursday, the Africa Centres for Disease Control and Prevention said mpox is still on the rise and that testing rates are “insufficient” across the continent.

Jason Kindrachuk, Canada research chair in emerging viruses at the University of Manitoba, said donating vaccines, in addition to supporting surveillance and diagnostic tests, is “massively important.”

But Kindrachuk, who has worked on the ground in Congo during the epidemic, also said that the international response to the mpox outbreak is “better late than never (but) better never late.”

“It would have been fantastic for us globally to not be in this position by having provided doses a much, much longer time prior than when we are,” he said, noting that the outbreak of clade I mpox in Congo started in early 2023.

Clade II mpox, endemic in regions of West Africa, came to the world’s attention even earlier — in 2022 — as that strain of virus spread to other countries, including Canada.

Two doses are recommended for mpox vaccination, so the donation may only benefit 100,000 people, Pai said.

Pai questioned whether Canada is contributing enough, as the federal government hasn’t said what percentage of its mpox vaccine stockpile it is donating.

“Small donations are simply not going to help end this crisis. We need to show greater solidarity and support,” he said in an email.

“That is the biggest lesson from the COVID-19 pandemic — our collective safety is tied with that of other nations.”

This report by The Canadian Press was first published Sept. 13, 2024.

Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

How many Nova Scotians are on the doctor wait-list? Number hit 160,000 in June

Published

 on

 

HALIFAX – The Nova Scotia government says it could be months before it reveals how many people are on the wait-list for a family doctor.

The head of the province’s health authority told reporters Wednesday that the government won’t release updated data until the 160,000 people who were on the wait-list in June are contacted to verify whether they still need primary care.

Karen Oldfield said Nova Scotia Health is working on validating the primary care wait-list data before posting new numbers, and that work may take a matter of months. The most recent public wait-list figures are from June 1, when 160,234 people, or about 16 per cent of the population, were on it.

“It’s going to take time to make 160,000 calls,” Oldfield said. “We are not talking weeks, we are talking months.”

The interim CEO and president of Nova Scotia Health said people on the list are being asked where they live, whether they still need a family doctor, and to give an update on their health.

A spokesperson with the province’s Health Department says the government and its health authority are “working hard” to turn the wait-list registry into a useful tool, adding that the data will be shared once it is validated.

Nova Scotia’s NDP are calling on Premier Tim Houston to immediately release statistics on how many people are looking for a family doctor. On Tuesday, the NDP introduced a bill that would require the health minister to make the number public every month.

“It is unacceptable for the list to be more than three months out of date,” NDP Leader Claudia Chender said Tuesday.

Chender said releasing this data regularly is vital so Nova Scotians can track the government’s progress on its main 2021 campaign promise: fixing health care.

The number of people in need of a family doctor has more than doubled between the 2021 summer election campaign and June 2024. Since September 2021 about 300 doctors have been added to the provincial health system, the Health Department said.

“We’ll know if Tim Houston is keeping his 2021 election promise to fix health care when Nova Scotians are attached to primary care,” Chender said.

This report by The Canadian Press was first published Sept. 11, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Newfoundland and Labrador monitoring rise in whooping cough cases: medical officer

Published

 on

 

ST. JOHN’S, N.L. – Newfoundland and Labrador‘s chief medical officer is monitoring the rise of whooping cough infections across the province as cases of the highly contagious disease continue to grow across Canada.

Dr. Janice Fitzgerald says that so far this year, the province has recorded 230 confirmed cases of the vaccine-preventable respiratory tract infection, also known as pertussis.

Late last month, Quebec reported more than 11,000 cases during the same time period, while Ontario counted 470 cases, well above the five-year average of 98. In Quebec, the majority of patients are between the ages of 10 and 14.

Meanwhile, New Brunswick has declared a whooping cough outbreak across the province. A total of 141 cases were reported by last month, exceeding the five-year average of 34.

The disease can lead to severe complications among vulnerable populations including infants, who are at the highest risk of suffering from complications like pneumonia and seizures. Symptoms may start with a runny nose, mild fever and cough, then progress to severe coughing accompanied by a distinctive “whooping” sound during inhalation.

“The public, especially pregnant people and those in close contact with infants, are encouraged to be aware of symptoms related to pertussis and to ensure vaccinations are up to date,” Newfoundland and Labrador’s Health Department said in a statement.

Whooping cough can be treated with antibiotics, but vaccination is the most effective way to control the spread of the disease. As a result, the province has expanded immunization efforts this school year. While booster doses are already offered in Grade 9, the vaccine is now being offered to Grade 8 students as well.

Public health officials say whooping cough is a cyclical disease that increases every two to five or six years.

Meanwhile, New Brunswick’s acting chief medical officer of health expects the current case count to get worse before tapering off.

A rise in whooping cough cases has also been reported in the United States and elsewhere. The Pan American Health Organization issued an alert in July encouraging countries to ramp up their surveillance and vaccination coverage.

This report by The Canadian Press was first published Sept. 10, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending